ReviewDrugs2018
Caplacizumab: First Global Approval.
Review in Drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 130 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.Blood advances · 2023Pooled it
- Nanobodies Open New Avenues in Cancer Treatment: From Molecular Engineering to Therapeutic Platforms.Cell biochemistry and biophysics · 2026Review
- Nanobody-based targeted cancer therapy and immunotherapy: fear not the future.Acta pharmacologica Sinica · 2026Review
- Nanobodies targeting SARS-CoV-2 variants.Acta pharmaceutica Sinica. B · 2026Review
- Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders.Thrombosis and haemostasis · 2026Review
- Article
- Surface Plasmon Resonance (SPR) Workflow for Comparative Analysis of Nanobody Variants Binding to Lysozyme as a Model Ligand.Current protocols · 2026Article
- Biopharmaceuticals for Cancer Treatment: An Update.Cancer medicine · 2026Review
- The complement factor B inhibitor iptacopan for relapsed and refractory immune thrombotic thrombocytopenic purpura.Thrombosis journal · 2026Article
- A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy.Journal of nanobiotechnology · 2026Article
- Nanobodies targeting the Epstein-Barr virus EBNA1 DNA binding domain inhibit tumor growth.Journal of nanobiotechnology · 2026Article
- Disulphide and sequence-encoded conformational priors guide nanobody structure prediction.bioRxiv : the preprint server for biology · 2026Article
- The impact of caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura. A retrospective monocentric cohort study.Frontiers in pharmacology · 2026Article
- Effectiveness of caplacizumab in the first-line treatment for acquired thrombotic thrombocytopenic purpura: single center experience.Therapeutic advances in hematology · 2026Article
- Delving into the innate and adaptive immunity of camelids: a paradigm of interspecies adaptation and evolutionary innovation.Frontiers in immunology · 2026Review
- Treating Immune-Mediated Thrombotic Thrombocytopenic Purpura with Caplacizumab.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Update in treatment options for congenital and immune thrombotic thrombocytopenic purpura.Frontiers in pharmacology · 2026Review
- Targeting vascular inflammation and endothelial dysfunction with nanobodies: emerging therapeutic strategies for cardiovascular disease.Frontiers in immunology · 2026Review
- Nanobodies in biomedicine: from molecular characteristics to fabrication and clinical translation.Military Medical Research · 2026Review
- Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.